Bacteriophage therapy for one patient with lung infection
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This is a special program for one patient with a lung infection from Mycobacterium abscessus. The trial uses a treatment with bacteriophages, which are viruses that attack specific bacteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be the specific patient being considered for this study.
- You must give your consent to participate.
- You must have a lung infection caused by Mycobacterium abscessus.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment using bacteriophages (viruses that attack specific bacteria) to fight a tough lung infection called Mycobacterium abscessus that doesn't respond to usual antibiotics. If you have this infection, this treatment might offer a new way to clear it.
This trial tests a new combination of antibiotics to treat a hard-to-cure lung infection caused by Mycobacterium abscessus. It compares the new combination to the standard treatment, and people with cystic fibrosis and those without can take part.
This study tests whether a new antibiotic, Contezolid, can quickly reduce the amount of Mycobacterium abscessus in your lungs. It may be a treatment option if you have had a positive sputum test in the past 6 months.
This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.
This study looks at how well phage therapy works for people with stubborn bacterial infections, like NTM. If your doctor is already considering phage therapy as part of your care, this trial may help track your response.
This study tests a new treatment that combines regular antibiotics with a special virus that attacks bacteria (called a phage) to fight lung infections that do not respond to standard antibiotics. It aims to see if this combination is safe and might help people with cystic fibrosis who have stubborn lung infections.
Hear when a new Mycobacterium Abscessus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.